1Nordestgaard B, Chapman M, Humphries S, et al. Familial hyper- cholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart dis- ease. Consensus Statement of the European Atheroosclerosis Society [J]. Euro Heart, 2013, 34(45) : 3 478-490.
2Mariko Harada-Shiba M, Arai H, Oikawa S, et al. Guidelines for the management of familial hypercholesterolemia [ J ]. Atheroscler Thromb, 2012, 19(12) : 1 043-060.
3Yamashita S, Hbujo H, Arai H, et al. Long-term probucol treat- ment prevents secondary cardiovascular events : a cohort study of pa- tients with heterozygous familial hypercholesterolemia in Japan [ J ]. J Atheroscler Thromb, 2008, 15(6): 292-301.
4Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation[ J]. J Clin Lipidol, 2014,8 (2) : 148-172.
5Dixon Dave L , Sisson Evan M , Butler Michael, et al. Lomitapide and Mipomersen:Novel Lipid-Lowering Agents for the Management of Familial Hypercholesterolemia[J]. J Cardiovas Nurs, 2014, 29 (5) :E7-E12.
6Paul E. Ziajka. Management of Patients With Homozygous Familial Hypercholesterolemia[ R]. And Managed Care, 2013, 19 ( 13 ) : $251 -$256.
7Lyseng-Willliamson, Katherine A, Perry, et al. Lomitapide : a guide to its use in adults with homozygous familial hypercholester- olemia in the EU [J]. Drugs And Therapy Perspectives, 2013, 29(12) : 373-378.
8Wilkinson M J, Davidson MH. Recent developments in the treat- ment of familial hypercholesterolemia: a review of several new drug classes[ J]. Curr Treat Options Cardiovasc Med, 2013, ( 15 ) : 696-705.
9Hovingh GK, Davidson MH, Kastelein JJ. et al. Diagnosis and treatment of familial hypercholesterelaemia [ J ]. Eur Heart J, 2013, 34 (13) : 962-971.
10Seidah NG. Preprotein Convertase Subtilisin Kexin 9 ( PCSK9 ) in- hibitors in the treatment of hypercholesterelemia and other patholo- gies[J]. Curt Pharm Des, 2013, t9(17) : 3 161-172.
